T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1876
Pathward Financial
CASH
$1.78B
| $1.52M | ﹤0.01% |
21,352
+1,159
| +6% | +$83.1K |
|
1877
MillerKnoll
MLKN
$1.64B
| $1.51M | ﹤0.01% |
82,847
+3,491
| +4% | +$56.9K |
|
1878
Sylvamo
SLVM
$1.53B
| $1.51M | ﹤0.01% |
31,458
+1,712
| +6% | +$77.9K |
|
|
DMC
1879
Del Monte Corp
DMC
$1.42B
| $1.51M | ﹤0.01% |
42,485
+1,134
| +3% | +$40.5K |
|
|
CALY
1880
Callaway Golf Company
CALY
$2.95B
| $1.51M | ﹤0.01% |
129,732
+8,488
| +7% | +$89.5K |
|
1881
Orchestra BioMed
OBIO
$266M
| $1.51M | ﹤0.01% |
364,645
-56,967
| -14% | -$230K |
|
1882
iShares 0-3 Month Treasury Bond ETF
SGOV
$101B
| $1.51M | ﹤0.01% |
15,014
-7
| -0% | -$703 |
|
1883
Universal Corp
UVV
$1.13B
| $1.5M | ﹤0.01% |
28,497
+759
| +3% | +$40.3K |
|
|
JBGS
1884
JBG SMITH
JBGS
$691M
| $1.5M | ﹤0.01% |
88,067
+2,884
| +3% | +$54.5K |
|
1885
The Greenbrier Companies
GBX
$1.42B
| $1.5M | ﹤0.01% |
32,025
+2,927
| +10% | +$131K |
|
1886
XPEL
XPEL
$1.35B
| $1.49M | ﹤0.01% |
29,797
+2,101
| +8% | +$87.8K |
|
1887
Constellium
CSTM
$3.95B
| $1.49M | ﹤0.01% |
78,838
-521,115
| -87% | -$8.65M |
|
1888
Concentrix
CNXC
$1.52B
| $1.49M | ﹤0.01% |
35,738
+1,543
| +5% | +$62.6K |
|
1889
Monopar Therapeutics
MNPR
$741M
| $1.49M | ﹤0.01% |
+22,727
| New | +$1.86M |
|
1890
Appian
APPN
$2.49B
| $1.48M | ﹤0.01% |
41,873
+2,813
| +7% | +$100K |
|
|
LTC
1891
LTC Properties
LTC
$2.1B
| $1.48M | ﹤0.01% |
43,159
+3,496
| +9% | +$123K |
|
1892
Neogen
NEOG
$2.5B
| $1.48M | ﹤0.01% |
211,833
+14,211
| +7% | +$89.4K |
|
1893
Dillards
DDS
$9.93B
| $1.48M | ﹤0.01% |
2,439
+97
| +4% | +$61.1K |
|
1894
Hope Bancorp
HOPE
$1.83B
| $1.47M | ﹤0.01% |
134,255
+7,349
| +6% | +$79.2K |
|
1895
Veeco
VECO
$3.26B
| $1.47M | ﹤0.01% |
51,403
-432,884
| -89% | -$12.8M |
|
1896
Boston Beer
SAM
$1.89B
| $1.47M | ﹤0.01% |
7,515
+480
| +7% | +$99K |
|
1897
Arlo Technologies
ARLO
$1.5B
| $1.47M | ﹤0.01% |
104,695
+4,507
| +4% | +$70.9K |
|
|
HOUS
1898
DELISTED
Anywhere Real Estate
HOUS
| $1.46M | ﹤0.01% |
103,204
-11,867
| -10% | -$145K |
|
1899
NeoGenomics
NEO
$2.11B
| $1.46M | ﹤0.01% |
123,930
+5,001
| +4% | +$54K |
|
1900
FMC
FMC
$1.27B
| $1.45M | ﹤0.01% |
104,697
-4,169
| -4% | -$79.5K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.